Cutaneous metastasis of ascending colon cancer harboring a BRAF V600E mutation A rare case report

被引:8
作者
Liao, Lianggong [1 ,2 ,3 ]
Cheng, Qian [1 ,2 ,3 ]
Zhu, Guangsheng [1 ,2 ,3 ]
Pei, Feng [1 ,2 ,3 ]
Ye, Shengwei [1 ,2 ,3 ]
机构
[1] Univ Sci & Technol, Hubei Canc Hosp, Tongji Med Coll, Dept Gastrointestinal Surg, Wuhan, Peoples R China
[2] Colorectal Canc Clin Res Ctr Wuhan, 116 Zuodaoquan South Rd, Wuhan, Hubei, Peoples R China
[3] Colorectal Canc Clin Res Ctr Hubei Prov, 116 Zuodaoquan South Rd, Wuhan, Hubei, Peoples R China
关键词
ascending colon cancer; case report; cetuximab; cutaneous metastasis; FOLFIRI; vemurafenib; SKIN; CARCINOMA;
D O I
10.1097/MD.0000000000020026
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Rationale: Cutaneous metastases from colorectal cancer are extremely rare and generally appear several years after diagnosis or resection of the primary colorectal tumor. Although cutaneous metastasis is unusual, it often indicates a poor prognosis. Patient concerns: We treated a 62-year-old woman with multiple cutaneous metastatic nodules on the chest, back, and armpit 7 months after resection of ascending colon cancer. Diagnoses: The patient was diagnosed with cutaneous metastasis of ascending colon cancer with BRAF V600E mutation. Interventions: After 6 cycles of fluorouracil, leucovorin, oxaliplatin, cetuximab, and emurafenib, most of the metastatic lesions had begun to shrink, and no new metastases were observed. Serum tests showed that the levels of several tumor markers were decreased. Outcomes: The patient responded well to treatment and survived for 6.5 months after presentation with skin metastasis. Lessons: Cutaneous metastasis of colorectal cancer with BRAF V600E mutation is a rare but important phenomenon that should not be ignored. Cutaneous metastasis of colorectal cancer frequently indicates advanced disease and poor prognosis. The SWOG 1406 program is one of the treatment options, but this needs further exploration.
引用
收藏
页数:5
相关论文
共 50 条
[31]   BRAF V600E mutation is a predictive indicator of upfront chemotherapy for stage IV colorectal cancer [J].
Morikawa, Tatsuya ;
Inada, Ryo ;
Nagasaka, Takeshi ;
Mori, Yoshiko ;
Kishimoto, Hiroyuki ;
Kawai, Takashi ;
Umeda, Yuzo ;
Mishima, Hideyuki ;
Goel, Ajay ;
Fujiwara, Toshiyoshi .
ONCOLOGY LETTERS, 2018, 15 (02) :2195-2201
[32]   VE1 immunohistochemistry predicts BRAF V600E mutation status and clinical outcome in colorectal cancer [J].
Schafroth, Christian ;
Galvan, Jose A. ;
Centeno, Irene ;
Koelzer, Viktor H. ;
Dawson, Heather E. ;
Sokol, Lena ;
Rieger, Gregor ;
Berger, Martin D. ;
Haedrich, Marion ;
Rosenberg, Robert ;
Nitsche, Ulrich ;
Schnueriger, Beat ;
Langer, Rupert ;
Inderbitzin, Daniel ;
Lugli, Alessandro ;
Zlobec, Inti .
ONCOTARGET, 2015, 6 (39) :41453-41463
[33]   Successful treatment of metastatic colorectal cancer with synchronous BRAF V600E mutation and dMMR with BGB-A317 [J].
Cheng, Yi ;
Fang, Xue-Feng ;
Hu, Han-Guang ;
Wang, Jiang ;
Sun, Li-Feng ;
Yuan, Ying .
IMMUNOTHERAPY, 2020, 12 (04) :229-234
[34]   The value of the repeated examination of BRAF V600E mutation status in diagnostics of papillary thyroid cancer [J].
Beisa, Augustas ;
Beisa, Virgilijus ;
Stoskus, Mindaugas ;
Ostaneviciute, Elvyra ;
Griskevicius, Laimonas ;
Strupas, Kestutis .
ENDOKRYNOLOGIA POLSKA, 2016, 67 (01) :35-40
[35]   Sustained response to vemurafenib in a low grade serous ovarian cancer with a BRAF V600E mutation [J].
Pierre Combe ;
Laure Chauvenet ;
Marie-Aude Lefrère-Belda ;
Hélène Blons ;
Caroline Rousseau ;
Stéphane Oudard ;
Eric Pujade-Lauraine .
Investigational New Drugs, 2015, 33 :1267-1270
[36]   BRAF (V600E) gene mutation in patients with thyroid cancer in Sri Lanka: A pilot study [J].
Ekanayaka, N. ;
Rathnayake, S. ;
Ratnayake, P. ;
Perera, K. ;
Udagama, P. .
JOURNAL OF THE NATIONAL SCIENCE FOUNDATION OF SRI LANKA, 2025, 53 (01) :3-12
[37]   BRAF V600E Mutational Status in Pediatric Thyroid Cancer [J].
Henke, Lauren E. ;
Perkins, Stephanie M. ;
Pfeifer, John D. ;
Ma, Changquing ;
Chen, Yumei ;
DeWees, Todd ;
Grigsby, Perry W. .
PEDIATRIC BLOOD & CANCER, 2014, 61 (07) :1168-1172
[38]   Targeted therapy with vemurafenib in BRAF(V600E)-mutated anaplastic thyroid cancer [J].
Lang, Matthias ;
Longerich, Thomas ;
Anamaterou, Chrysanthi .
THYROID RESEARCH, 2023, 16 (01)
[39]   Three-target treatment combined with surgery for BRAF V600E-mutant colon cancer with peritoneal metastasis: a case report [J].
Li, Hong-Xia ;
Zhang, Xiao-Lan ;
Zhang, Jun-Qing ;
Cai, Min ;
Li, Sheng-Wen .
JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2022, 13 (05) :2647-2653
[40]   A case of an epithelioid glioblastoma with the BRAF V600E mutation colocalized with BRAF intact low-grade diffuse astrocytoma [J].
Kuroda, Jun-Ichiro ;
Nobusawa, Sumihito ;
Nakamura, Hideo ;
Yokoo, Hideaki ;
Ueda, Ryuta ;
Makino, Keishi ;
Yano, Shigetoshi ;
Kuratsu, Jun-ichi .
NEUROPATHOLOGY, 2016, 36 (02) :181-186